Subcutaneous (SC) abatacept — Competitive Intelligence Brief

Subcutaneous (SC) abatacept (Subcutaneous (SC) abatacept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell costimulation modulator. Area: Immunology.

phase 3 T-cell costimulation modulator CD80/CD86 Immunology Small molecule

Target snapshot

Subcutaneous (SC) abatacept (Subcutaneous (SC) abatacept) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Subcutaneous (SC) abatacept TARGET	Subcutaneous (SC) abatacept	Bristol-Myers Squibb	phase 3	T-cell costimulation modulator	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
ABT	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
Open-label Abatacept	Open-label Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell costimulation inhibitor)	CD80/CD86
Abatacept (W12-W48)	Abatacept (W12-W48)	University Hospital, Montpellier	phase 3	T-cell costimulation inhibitor	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell costimulation modulator class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Massachusetts General Hospital · 1 drug in this class